User login

Facebook Connect

New ASPC Manual of Preventive Cardiology

Endorsed by the American Society of Preventive Cardiology, this highly practical resource focuses on the application of current guidelines and practice standards in the clinical management of cardiovascular risk factors. The Manual presents concise descriptions of each major cardiovascular risk factor, and practical, to-the-point discussions of current best practices in clinical management.

Read More

FDA Approves Expanded Indication for Brilinta (Ticagrelor) to Include Long-Term Use in Patients with a History of Heart Attack

AstraZeneca announced that the U.S Food and Drug Administration’s (FDA) approved Brilinta (ticagrelor) at a new dose of 60 mg twice-daily to be used in patients with a history of heart attack beyond the first year. Ticagrelor is produced by AstraZeneca, and known by the brand name Brilinta.

The FDA first approved ticagrelor in July 2011 on the basis of data from the PLATO study that was published in the New England Journal of Medicine

Read More

ASPC Debate Live From EPI-NPAM 2014

Listen to the different views of Martin Gibala, MD and William Krause, MD as they discuss "Exercise and Health - Does Intensity Matter?". Click here for audio and slides.

Read More

President's Message

President Laurence S. Sperling, M.D., FACC, FAHA, FACP is the Founder and Director of Preventive Cardiology at the Emory Clinic and Co-Director of the Cardiovascular Disease Fellowship Program at Emory. Read More